A new PGen study reports that nearly 6 percent of consumers made changes to their prescription medication based on pharmacogenomic testing.
Under the terms of the agreement, M3 and G-TAC will promote 14 Pathway tests through G-TAC's personalized medicine platform connected to M3's physician network.
Researchers examined the patient-physician relationship after sharing personal genetic testing results and found that patients may have certain expectations.
Researchers from Brigham and Women's and Harvard surveyed more than 1,600 new customers of 23andMe or Pathway Genomics in the US, of whom 80 were adopted.
The company said it would use the funds to expand its genomic test pipeline, grow its sales force, and invest in new technologies for its laboratories.
The US Department of Justice sued the company for paying doctors to perform its genomic tests, and then obtaining government reimbursements.
The US Food and Drug Administration has sent a letter this week to Pathway Genomics regarding its liquid biopsy cancer screening test.
The agency has sent a letter to the company requesting a meeting to discuss the recently launched liquid biopsy test, saying it may run afoul of FDA rules and regulations.
More data may be needed for blood-based cancer-screening tests to show their worth, say Tech Review's Antonio Regalado and the Verge's Arielle Duhaime-Ross.
The test, called CancerIntercept Detect, is aimed at the early discovery of malignancies in asymptomatic people with an elevated risk of developing cancer, and can be ordered directly through Pathway and its online doctor network.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.